Study Categories

Official Title

Improving emergency care and outcomes of immune-related adverse events: The immune related emergency disposition index (irEDI)

Purpose

The purpose of this study is to learn more about how to best care for patients who have immune-related side effects and have received treatment with an immune checkpoint inhibitor. 

The duration of this study is 30 days. 

Could this study be right for you?

• Must speak English and/or Spanish
• Diagnosis of cancer (excluding non-melanoma skin cancer)
• Last immunotherapy received within 90 days of study enrollment

Age Range

18 years and up

Official Title

Effect of Glucose Fluctuations on Atrial Fibrillation Burden among Patients with Diabetes Mellitus and Paroxysmal Atrial Fibrillation or Recent Atrial Fibrillation Ablation

Purpose

The purpose of this study is to examine the effects of glucose levels on atrial fibrillation episodes in people with diabetes and history of atrial fibrillation.

The duration of the study lasts 6 months. 

Could this study be right for you?

• Participants diagnosed with type 2 diabetes mellitus
• Body mass index between 25 and 45 kg/m2
• Insulin use at least 10 units per day or more than 1 glucose lowering medication with a hemoglobin A1c greater than 7%
• ICM placement
• Paroxysmal atrial fibrillation (irregular heartbeat that goes back to normal after a week) or atrial fibrillation ablation (procedure to treat irregular heartbeat) within 30 days

Age Range

40 - 79 years

Official Title

Retirement from Contact Sports after Concussion

Purpose

The purpose of this study is to understand the experiences of children and young adults after medical retirement from contact sports due to concussion(s).

Participants and their parent(s) will complete online questionnaires (about 10 minutes) at the time of enrollment. You will then be scheduled for an interview (about 30 minutes) by video meeting or phone.

Could this study be right for you?

• Children and young adults who have retired from contact sports or other high-risk activities (i.e. dirt bike riding, downhill skiing...) due to prior concussion.  
• Parents may participate if their child enrolls.

Age Range

14 - 22 years

Official Title

A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Effectiveness of CIN-107 for the Management of Blood Pressure in Patients with Primary Aldosteronism

Purpose

The purpose of this study is to see how the study drug CIN-107 works in managing blood pressure in patients with primary aldosteronism (PA), a hormone disorder which causes your body to produce too much of the hormone aldosterone.

The duration of this study is 74 weeks. 

Could this study be right for you?

• Diagnosis of primary aldosteronism (PA)
• Taking an MRA to control BP, such as Spironolactone or Eplerenone, or not yet taking an MRA

Age Range

18 and up

Official Title

Safety, Tolerability, and Outcomes of Velpatasvir/SofosbuviR in Treatment of Chronic Hepatitis C Virus during Pregnancy (STORC), pregnant woman

Purpose

This study involves evaluating a medication for hepatitis C in pregnant women. 

If you are a pregnant woman with chronic hepatitis C and you join the study, you are consenting to enroll yourself and your baby after he/she is born.

Maternal participants will have 7 visits over approximately 7 months. Infant participants have four visits over approximately the first year of life.

Could this study be right for you?

(This is not a complete list)  

- Must be  18 - 45 years of age

- Chronic HCV infection of at least 6 months

- Singleton pregnancy at 20 + 0 to 30 + 0 weeks’ gestation

- Documented negative Hepatitis B testing for current infection (negative HBsAg test) prior to enrollment

- If living with HIV, must be on antiretroviral therapy

 

Exclusion Criteria (not a complete list)

- Plans to relocate away from the study site area in the next 16 months and unable/unwilling to return for study visits

- History of cirrhosis

- Known fetal chromosomal abnormality prior to enrollment

Age Range

18 - 45

Official Title

Addressing the double jeopardy of stress and hypertension among African American female caregivers of persons living with Alzheimer’s disease and related dementias (R21)

Purpose

The purpose of this study is to determine the feasibility of a group delivered intervention for stress and blood pressure in African American women caregivers.

Could this study be right for you?

• Diagnosis of HTN treated with an antihypertensive medication or risk of HTN that includes obesity and high cholesterol
• Age 40 and older
• A caregiver rating of the PLWD of 2 or greater on the Alzheimer’s Dementia-8 scale
• Caregiver provides unpaid care to a PLWD at least 10 hours per week or assists with at least one instrumental activity of daily living
• Self-identifies as Black/African American
• English speaking
• Access to a telecommunications device such as the internet via desktop, laptop/tablet, smartphone, or telephone

Age Range

40 and up

Official Title

Evaluating the effect of a WearIng a TENS-device in NausEa Relief (The WINNER Study)

Purpose

The purpose of this study is to evaluate if this wearable device can help manage nausea in those who suffer from this problem chronically. 

If you choose to participate, then you will be given the study device to wear on your wrist for 12 weeks. In the weeks before and during this time, you will complete a series of daily and weekly questionnaires about your nausea symptoms, mood, sleep, and bowel habits.

Could this study be right for you?

• Nausea going on for more than 2 months
• 18 years or older
• Able to understand English
• Seen at OSU for their care
• Able to complete surveys online using either smart phone or computer

Age Range

18 and up

Official Title

Where Do Franklin County Residents Overdose and What Supports Do They Need?

Purpose

The purpose of this study is to identify places where Franklin County residents have had an opioid-related overdose (e.g. home, workplace, coffee shop, grocery story). We also want to identify what resources people want to see in these places (e.g. NaloxBoxes, vending machines, a motion monitoring device) to help people stay safe.

Could this study be right for you?

• Male and females aged 18 years or older
• Resident of Franklin County
• Experienced at least one overdose in Franklin County, OH between January 2021 and December 2022
• You suspected your overdose was opioid-related or someone gave you Narcan
• Willing to discuss your overdose experience in a one-on-one interview
• Have access to a private room and an Internet connection, or able to travel to a local public library for the interview

Age Range

18 and up

Official Title

Orexin Receptor Antagonists as Modulators of Threat Sensitivity in individuals with Alcohol Use Disorder

Purpose

The purpose of this study is to see if BELSOMRA, an FDA approved medication that is prescribed to treat insomnia, changes the body’s response to stress. Participation in the study includes 3 or 5 in-person lab visits (depending on randomization), which include EEG and MRI. Nearly all visits are 1.5 hours long, with the exception of one that is 4-5 hours in duration. Visits are flexible and scheduled at your convenience. Participants take the medication (or placebo) for 4 weeks, during which participation is only composed of virtual surveys via a smartphone app.

The total length of participation in the study is 1.5-2 months depending on scheduling/availability.

Could this study be right for you?

Eligibility Criteria:

• 18-65 years old
• Generally medically and physically healthy
• Regular alcohol use

Exclusion Criteria:

• Diagnosis of bipolar disorder, schizophrenia, mania, or psychosis
• Currently pregnant or trying to become pregnant (female)
• Presence of ferrous-containing metal in the body
• Inability to tolerate enclosed spaces
   

Exclusion Criteria varies, please contact Study Coordinator for more information.

Age Range

18 - 65

Official Title

A Phase I Study to Assess the Safety, Tolerability and Preliminary Efficacy of AAV2-BDNF [Adeno-Associated Virus (AAV)-based, Vector-Mediated Delivery of Human Brain Derived Neurotrophic Factor] in Subjects with Early Alzheimer’s Disease and Mild Cognitive Impairment

Purpose

The primary aim of this study is to determine whether administration of the nervous system growth factor "Brain-Deruved Neurotrophic Factor" (BDNF) to eligible patients with Alzheimer's disease and Mild Cognitive Impairment is safe and tolerable. This study will be used to determine whether BDNF administration reduces neuronal loss and rebuilds synapses in the brain of patients with Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI). 

Could this study be right for you?

• Male and Females aged 50 years or older
• Diagnosis of dementia due to Alzheimer's Disease/Diagnosis of Mild Cognitive Impairment (MCI) due to Alzheimer’s Disease
• A caregiver is available who has frequent contact with the subject, agrees to observe for adverse events, and will accompany the subject to all clinic visits for the duration of the protocol
• CT or MRI scans within 24 months prior to screening without evidence of an infection, infarction, or other focal 

Inclusion Criteria varies, please contact Study Coordinator for more information.

The below Exclusion Criteria apply to both the AD and MCI groups.

• Any significant neurological disease other than suspected incipient disease
• History of schizophrenia 
• History of systemic cancer within the past 18 months (non-metastatic skin cancers are acceptable).
• Any significant systemic illness or unstable medical conditions which could lead to difficulty complying with the protocol
• Use of any investigational drugs within thirty days or five half-lives, whichever is longer, prior to screening.

Exclusion Criteria varies, please contact Study Coordinator for more information. 

Age Range

50 and up

Official Title

A Study About Biomarkers for Evaluating Spine Treatments

Purpose

The purpose of this research study is to study four treatments for chronic low-back pain to learn whether or not certain treatments work better for people with certain characteristics.

The study’s main goal is to find a way to match treatments to low-back pain patients based on their characteristics and how they responded to treatments they have used before.
 

Could this study be right for you?

Inclusion Criteria:

To be eligible, an individual must meet all of the following inclusion criteria:

• Ability to read and understand English
• Provision of signed and dated informed consent form(s)
• Willing and able to receive study-related messages and survey links via email
• Willing and able to receive study-related phone calls
• Age 18 years old or older
• Low-back pain for at least 3 months and occurring on at least half the days in the past 6 months
• Contraindicated to no more than one of the study interventions at the time of eligibility assessment(s)
• Eligible to receive at least three of the four study interventions and willing to receive any intervention for which they are eligible
• A PEG score 4 or higher at two time points: 1) screening prior to the Run-in period and 2) screening prior to baseline (Visit 0)
• Willing and able to undergo required phenotyping
• Regular reliable access to an internet-enabled device such as a smart phone, tablet, or laptop computer

• Meet Run-in period engagement eligibility criteria:

  • Completion of two Run-in study information modules prior to period 1 randomization (Visit 0)
  • Response to at least 5 emails prior to period 1 randomization (Visit 0)
• Low-back pain more severe than pain in other parts of the body
• Available to complete the full study protocol (approximately 9 months)

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

• Pregnant at the time of Visit 0 (Baseline)

• Affirmative participant response to any of the following conditions:

  • Progressive neurodegenerative disease
  • History of discitis osteomyelitis (spine infection) or spine tumor
  • History of ankylosing spondylitis, rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, or lupus
  • History of cauda equina syndrome or spinal radiculopathy with functional motor deficit (strength <4/5 on manual motor testing)
  • Diagnosis of any vertebral fracture in the last 6 months
  • Osteoporosis requiring pharmacologic treatment other than vitamin D, calcium supplements, or bisphosphonates.
  • History of any bone-related cancer or cancer that metastasized to the bone
  • Currently in treatment for any non-skin cancer or plan to start non-skin cancer treatment in the next 12 months
  • History of any non-skin cancer treatment in the last 24 months
  • Visual or hearing difficulties that would preclude participation
  • Uncontrolled drug/alcohol addiction
  • Individuals actively pursuing disability or workers compensation or involved in active personal injury-related litigation
  • Currently participating in another interventional pain study
• Any condition that, in the opinion of the investigator, would preclude the patient from being able to safely participate in in the trial

Age Range

18 and up

Official Title

An Intervention Study about Primary Care Algorithms for Early Identification of Young Women with von Willebrand Disease

Purpose

Researchers at Nationwide Children’s Hospital are seeking volunteers to be a part of a study looking at how to best screen for bleeding disorders in young women.

Participants will be asked to undergo a finger prick blood test and complete questionnaires. If their survey answers suggest they have heavy menses or abnormal bleeding, they will also be asked to have a blood draw on the same day.

Could this study be right for you?

• Are 9 to 21 years old
• Have had your first menstrual cycle

Age Range

9 - 21